Review

rabbit anti-cd8a polyclonal antibody (ABclonal Biotechnology)

ABclonal Biotechnology is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ABclonal Biotechnology rabbit anti-cd8a polyclonal antibody

D-Nap-GFFY-T317 inhibits formation of urethane-induced lung tumors and atypical hyperplasia in WT but not IFNγ -/- mice. ( A ) WT or IFNγ -/- mice were randomly divided into 3 groups, and received following treatment: NC group, fed normal chow; TF group, fed normal chow containing T317 (5 mg/day/kg bodyweight); TH group, fed normal chow and s.c. injected D-Nap-GFFY once another day with dose of T317 at 10 mg/kg bodyweight or 5 mg/day/kg bodyweight. After one week of treatment, all the mice were i.p. injected urethane (1 g/kg bodyweight) once every 3 days for 8 times. After 126 days of the 1 st time urethane injection, all mice were sacrificed followed by collection of lung samples. ( B ) all lung samples were checked the tumor incidence on lung surface. ( C-D ) lung was photographed, the number of macroscopic external pulmonary nodules was counted. Arrows indicate the representative tumors. ( E-F ) after preparation, lung sections were conducted HE staining to determine tumor area with quantitative assay as % of whole section. ( G-L ) lung sections were conducted IHC staining to determine expression of <t>Ki-67,</t> <t>TTF-1</t> and <t>SPC</t> with quantitative analysis of the average optical density (AOD) value (n ≥ 4). NEC: negative control, normal IgG was used to replace primary antibody. *P < 0.05, **P < 0.01, ***P < 0.001; NS: not significantly different. n = 14 for WT mice, n ≥ 8 for IFNγ -/- mice as indicated in Table .

Rabbit Anti Cd8a Polyclonal Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-cd8a+polyclonal+antibody/pmc07806465-266-2-11?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews

rabbit anti-cd8a polyclonal antibody - by Bioz Stars, 2026-07

90/100 stars

Images

1) Product Images from "Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis"

Article Title: Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis

Journal: Theranostics

doi: 10.7150/thno.53139

Figure Legend Snippet: D-Nap-GFFY-T317 inhibits formation of urethane-induced lung tumors and atypical hyperplasia in WT but not IFNγ -/- mice. ( A ) WT or IFNγ -/- mice were randomly divided into 3 groups, and received following treatment: NC group, fed normal chow; TF group, fed normal chow containing T317 (5 mg/day/kg bodyweight); TH group, fed normal chow and s.c. injected D-Nap-GFFY once another day with dose of T317 at 10 mg/kg bodyweight or 5 mg/day/kg bodyweight. After one week of treatment, all the mice were i.p. injected urethane (1 g/kg bodyweight) once every 3 days for 8 times. After 126 days of the 1 st time urethane injection, all mice were sacrificed followed by collection of lung samples. ( B ) all lung samples were checked the tumor incidence on lung surface. ( C-D ) lung was photographed, the number of macroscopic external pulmonary nodules was counted. Arrows indicate the representative tumors. ( E-F ) after preparation, lung sections were conducted HE staining to determine tumor area with quantitative assay as % of whole section. ( G-L ) lung sections were conducted IHC staining to determine expression of Ki-67, TTF-1 and SPC with quantitative analysis of the average optical density (AOD) value (n ≥ 4). NEC: negative control, normal IgG was used to replace primary antibody. *P < 0.05, **P < 0.01, ***P < 0.001; NS: not significantly different. n = 14 for WT mice, n ≥ 8 for IFNγ -/- mice as indicated in Table .

Techniques Used: Injection, Staining, Immunohistochemistry, Expressing, Negative Control

Image Search Results

( A ) Representative digital three-dimensional (3D) rendering from MRI images of 4-month-old STING-sufficient Nf1 f/f ; DhhCre and STING-deficient STING gt/gt ; Nf1 f/f ; DhhCre. ( B ) Quantification of PNF volume. ( C ) Representative gross dissections of mice with WT STING and mutant STING at 7 months old. ( D ) Quantification of the number of tumors. ( E ) Representative hematoxylin and eosin (H&E) stain, toluidine blue stain for mast cells, and Iba-1 for macrophages. ( F ) PNF flow cytometer of Nf1 f/f ; DhhCre or STING gt/gt Nf1 f/f ; DhhCre mice for MHCII + CD11c + CD172a − XCR-1 + cDC1 and MHCII + CD11c + CD172a + XCR-1 − cDC2 DCs, ( G ) TCRβ + T cells and ( H ) CD4 and CD8 T cells with ( I ) represented analysis of activation markers (CD44 and CD69). Statistical significance ( P < 0.05). n.s., not significant. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, *** P < 0.003, and **** P < 0.0001.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Representative digital three-dimensional (3D) rendering from MRI images of 4-month-old STING-sufficient Nf1 f/f ; DhhCre and STING-deficient STING gt/gt ; Nf1 f/f ; DhhCre. ( B ) Quantification of PNF volume. ( C ) Representative gross dissections of mice with WT STING and mutant STING at 7 months old. ( D ) Quantification of the number of tumors. ( E ) Representative hematoxylin and eosin (H&E) stain, toluidine blue stain for mast cells, and Iba-1 for macrophages. ( F ) PNF flow cytometer of Nf1 f/f ; DhhCre or STING gt/gt Nf1 f/f ; DhhCre mice for MHCII + CD11c + CD172a − XCR-1 + cDC1 and MHCII + CD11c + CD172a + XCR-1 − cDC2 DCs, ( G ) TCRβ + T cells and ( H ) CD4 and CD8 T cells with ( I ) represented analysis of activation markers (CD44 and CD69). Statistical significance ( P < 0.05). n.s., not significant. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, *** P < 0.003, and **** P < 0.0001.

Article Snippet: The following antibodies were used: phospho-STING (Ser 366 ) (E9A9K) rabbit monoclonal antibody (mAb) (Cell Signaling Technology), phospho-STING (Ser 365 ) (D1C4T) rabbit mAb (no. 62912, Cell Signaling Technology), phospho-STING (Ser 366 ) (E9A9K) rabbit mAb (no. 50907, Cell Signaling Technology), phospho-IRF3 (Ser 396 ) (4D4G) rabbit mAb (Cell Signaling Technology), phospho-TBK1/NAK (Ser 172 ) (D52C2) XP rabbit mAb (Cell Signaling Technology), phospho-IRF3 (Ser 396 ) (D6O1M) rabbit mAb (no. 29047S), F4/80 (BM8.1) rat mAb (Cell Signaling Technology), mouse CCR5 antibody (MAB6138-SP, Thermo Fisher Scientific), CoraLite488 anti-mouse TCRβ (H57-597) (CL488-65106, Proteintech), anti-CD4 rabbit polyclonal antibody (BS-0647R, Bioss Antibodies), anti-CD8A rabbit polyclonal antibody (BS-0648R, Bioss Antibodies), XCR1 (D2F8T) rabbit mAb (no. 44665S, Cell Signaling Technology), CD103/INGAE (integrin alpha e) (EP206) rabbit mAb (no. 95835S, Cell Signaling Technology), anti-CD8 antibody, rabbit monoclonal (clone SP16) (SAB5500074, Sigma-Aldrich), CD3ε (E4T1B) XP Rabbit mAb (no. 78588, Cell Signaling Technology), and Iba-1 rabbit polyclonal (no. 019-19741, Wako).

Techniques: Mutagenesis, Staining, Flow Cytometry, Activation Assay

( A ) Schematic diagram of STING inhibitor (STINGi; H-151) treatment regimen. ( B ) Representative images of gross dissected paraspinal tumors from vehicle or H-151–treated mice and the corresponding graphical quantification of tumor numbers and size. ( C ) Representative images of IHC against p-STING, p-TBK1, and p-IRF3 and ( D ) quantified in vehicle versus H-151–treated mice. ( E ) Toluidine blue staining for mast cells, immunostaining of Iba-1 for detection of macrophages and CD3 for T cells in vehicle and H-151–treated groups and ( F ) quantified wherein each panel and each dot represents data from a single mouse, in which 5 HPF (high-power field) were analyzed per animal. ( G and H ) Flow cytometric quantification of activated (CD44hi CD69hi) CD8 T cells and cDC1 in vehicle or H-151–treated mice. Student’s t-test: * P < 0.05; ** P < 0.001.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Schematic diagram of STING inhibitor (STINGi; H-151) treatment regimen. ( B ) Representative images of gross dissected paraspinal tumors from vehicle or H-151–treated mice and the corresponding graphical quantification of tumor numbers and size. ( C ) Representative images of IHC against p-STING, p-TBK1, and p-IRF3 and ( D ) quantified in vehicle versus H-151–treated mice. ( E ) Toluidine blue staining for mast cells, immunostaining of Iba-1 for detection of macrophages and CD3 for T cells in vehicle and H-151–treated groups and ( F ) quantified wherein each panel and each dot represents data from a single mouse, in which 5 HPF (high-power field) were analyzed per animal. ( G and H ) Flow cytometric quantification of activated (CD44hi CD69hi) CD8 T cells and cDC1 in vehicle or H-151–treated mice. Student’s t-test: * P < 0.05; ** P < 0.001.

Techniques: Staining, Immunostaining

( A ) Representative IHC images of human nerve or neurofibroma biopsies for the detection of TCRβ T cells and ( B ) double labeling for TCRβ (brown) with CD4 or CD8 (red) T cells and CD11c (brown) and XCR-1 (red) for DCs. ( C ) Representative IHC images WT DRG or Nf1 f/f ; DhhCre neurofibroma. ( D ) Representative flow cytometric analysis of TCRβ + CD3 + T cells and quantification. ( E ) CD4 and CD8 T cells subtypes and in PNF tissue corresponding flow cytometric quantification. ( F ) Immunofluorescence showing CD4 and CD8 T cells subtypes in neurofibroma tissues. ( G ) Representative flow cytometric analysis of antigen primed and activation marker CD44 high CD69 high of CD4 or CD8 T cell subpopulation from a WT DRG or Nf1 f/f ; DhhCre neurofibromas and graphical quantification showing frequency of effector T cells indicated by CD44 + CD69 + expression of CD4 or CD8 T cells. ( H ) Flow cytometric analysis of conventional DCs gated from MHCII + and CD11c + cells in WT DRG or Nf1 f/f ; DhhCre neurofibromas with corresponding quantification of Xcr-1 + (cDC1) and Sirpα + (cDC2). ( I ) Flow cytometric quantification of B cells marked by CD19 + cells in Nf1 f/f ; DhhCre neurofibroma compared to those in WT DRG. Data represent means ± SD; t test, P < 0.05. DAPI, 4′,6-diamidino-2-phenylindole. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, and *** P < 0.003.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Representative IHC images of human nerve or neurofibroma biopsies for the detection of TCRβ T cells and ( B ) double labeling for TCRβ (brown) with CD4 or CD8 (red) T cells and CD11c (brown) and XCR-1 (red) for DCs. ( C ) Representative IHC images WT DRG or Nf1 f/f ; DhhCre neurofibroma. ( D ) Representative flow cytometric analysis of TCRβ + CD3 + T cells and quantification. ( E ) CD4 and CD8 T cells subtypes and in PNF tissue corresponding flow cytometric quantification. ( F ) Immunofluorescence showing CD4 and CD8 T cells subtypes in neurofibroma tissues. ( G ) Representative flow cytometric analysis of antigen primed and activation marker CD44 high CD69 high of CD4 or CD8 T cell subpopulation from a WT DRG or Nf1 f/f ; DhhCre neurofibromas and graphical quantification showing frequency of effector T cells indicated by CD44 + CD69 + expression of CD4 or CD8 T cells. ( H ) Flow cytometric analysis of conventional DCs gated from MHCII + and CD11c + cells in WT DRG or Nf1 f/f ; DhhCre neurofibromas with corresponding quantification of Xcr-1 + (cDC1) and Sirpα + (cDC2). ( I ) Flow cytometric quantification of B cells marked by CD19 + cells in Nf1 f/f ; DhhCre neurofibroma compared to those in WT DRG. Data represent means ± SD; t test, P < 0.05. DAPI, 4′,6-diamidino-2-phenylindole. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, and *** P < 0.003.

Techniques: Labeling, Immunofluorescence, Activation Assay, Marker, Expressing

( A ) Representative image of gross dissection of the spinal cord with attached DRG or tumors of Nf1 f/f ; DhhCre mice with heterozygous or homozygous loss of Batf3 transcription factor necessary for cDC1 development. ( B and C ) Quantification of the number of tumors and size in Nf1 f/f ; DhhCre mice with or without cDC1 subset deficiency. ( D ) Representative H&E and S100B staining of DRG/tumors from Nf1 f/f ; DhhCre or Batf3 −/− ; Nf1 f/f ; DhhCre mice. ( E ) Flow cytometric analysis of cDC1 (Xcr-1 + ) and cDC2 (SIRPα + ) population in Nf1 f/f ; DhhCre or Batf3 −/− ; Nf1 f/f ; DhhCre tumors. ( F and G ) Representative flow cytometry and quantification of activated (CD44 + CD69 + ) CD4 or CD8 T cells. ( H ) Electron micrographs of the saphenous nerve of 7-month-old WT control, Nf1 f/f ; DhhCre neurofibroma, and Batf3 −/− ; Nf1 f/f ; DhhCre mice and quantification of intact Remak bundle. Scale bar, 100 μm. Student’s t-test: *adj. * P < 0.05, *** P < 0.003, and **** P < 0.0001.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Representative image of gross dissection of the spinal cord with attached DRG or tumors of Nf1 f/f ; DhhCre mice with heterozygous or homozygous loss of Batf3 transcription factor necessary for cDC1 development. ( B and C ) Quantification of the number of tumors and size in Nf1 f/f ; DhhCre mice with or without cDC1 subset deficiency. ( D ) Representative H&E and S100B staining of DRG/tumors from Nf1 f/f ; DhhCre or Batf3 −/− ; Nf1 f/f ; DhhCre mice. ( E ) Flow cytometric analysis of cDC1 (Xcr-1 + ) and cDC2 (SIRPα + ) population in Nf1 f/f ; DhhCre or Batf3 −/− ; Nf1 f/f ; DhhCre tumors. ( F and G ) Representative flow cytometry and quantification of activated (CD44 + CD69 + ) CD4 or CD8 T cells. ( H ) Electron micrographs of the saphenous nerve of 7-month-old WT control, Nf1 f/f ; DhhCre neurofibroma, and Batf3 −/− ; Nf1 f/f ; DhhCre mice and quantification of intact Remak bundle. Scale bar, 100 μm. Student’s t-test: *adj. * P < 0.05, *** P < 0.003, and **** P < 0.0001.

Techniques: Dissection, Staining, Flow Cytometry, Control

( A ) Schematic diagram of the T cell proliferation assay: CD8 + T cells were purified by negative selection using a Miltenyi kit. T cells from tumor-bearing mice were labeled with CFSE and mixed with APCs from WT or tumor-bearing Nf1 f/f ; DhhCre mice. Four days later, cells were harvested and assessed for CFSE dilution. Graph shows the percent of CD8 + T cells that had proliferated (CFSE low). ( B ) Quantification on proliferating CD8 T cells from WT mice cocultured with APC from WT or Nf1 f/f ; DhhCre mice. ( C ) CD8 T cell proliferation from Nf1 f/f ; DhhCre mice cocultured with APC from WT or Nf1 f/f ; DhhCre mice. (C) Representative images of gross dissections of mouse spinal cord with the associated neurofibromas of the dorsal root in Nf1 f/f ; DhhCre mice not observed in Rag1 −/− ; Nf1 f/f ; DhhCre mice that lack adaptive immune cells at 7 months of age. ( D ) Quantification of the number of tumors observed per mouse and tumor diameters between Nf1 f/f ; DhhCre and Rag1 −/− ; Nf1 f/f ; DhhCre mice. ( E ) Representative tissue histochemistry of DRGs/PNF in Nf1 f/f ; DhhCre or Rag1 −/− ; Nf1 f/f ; DhhCre stained with H&E, S100β, and Ki67. ( F ) Immunofluorescence of Iba-1 + macrophages in DRG or neurofibromas, and the number of Iba-1 + per field of view (FOV). ( G ) Toluidine blue stain for detection of mast cells, and the number of toluidine blue–positive mast cells per field of view. ( H ) Electron micrographs of the saphenous nerve of 7-month-old WT control, Nf1 f/f ; DhhCre neurofibroma, and Rag1 −/− ; Nf1 f/f ; DhhCre mice. ( I ) Quantification of intact Remak bundle. * P < 0.05; Student’s t-test: **adj. ** P < 0.001; *** P < 0.003, and **** P < 0.0001.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Schematic diagram of the T cell proliferation assay: CD8 + T cells were purified by negative selection using a Miltenyi kit. T cells from tumor-bearing mice were labeled with CFSE and mixed with APCs from WT or tumor-bearing Nf1 f/f ; DhhCre mice. Four days later, cells were harvested and assessed for CFSE dilution. Graph shows the percent of CD8 + T cells that had proliferated (CFSE low). ( B ) Quantification on proliferating CD8 T cells from WT mice cocultured with APC from WT or Nf1 f/f ; DhhCre mice. ( C ) CD8 T cell proliferation from Nf1 f/f ; DhhCre mice cocultured with APC from WT or Nf1 f/f ; DhhCre mice. (C) Representative images of gross dissections of mouse spinal cord with the associated neurofibromas of the dorsal root in Nf1 f/f ; DhhCre mice not observed in Rag1 −/− ; Nf1 f/f ; DhhCre mice that lack adaptive immune cells at 7 months of age. ( D ) Quantification of the number of tumors observed per mouse and tumor diameters between Nf1 f/f ; DhhCre and Rag1 −/− ; Nf1 f/f ; DhhCre mice. ( E ) Representative tissue histochemistry of DRGs/PNF in Nf1 f/f ; DhhCre or Rag1 −/− ; Nf1 f/f ; DhhCre stained with H&E, S100β, and Ki67. ( F ) Immunofluorescence of Iba-1 + macrophages in DRG or neurofibromas, and the number of Iba-1 + per field of view (FOV). ( G ) Toluidine blue stain for detection of mast cells, and the number of toluidine blue–positive mast cells per field of view. ( H ) Electron micrographs of the saphenous nerve of 7-month-old WT control, Nf1 f/f ; DhhCre neurofibroma, and Rag1 −/− ; Nf1 f/f ; DhhCre mice. ( I ) Quantification of intact Remak bundle. * P < 0.05; Student’s t-test: **adj. ** P < 0.001; *** P < 0.003, and **** P < 0.0001.

Techniques: Proliferation Assay, Purification, Selection, Labeling, Staining, Immunofluorescence, Control

( A ) Schematic of CD8 T cell depletion. ( B ) Flow cytometric quantification in the proportion of CD4 or CD8 of the total blood CD3 T cells in Nf1 f/f ; DhhCre compared to that in Rag1 −/− ; Nf1 f/f ; DhhCre. ( C ) Percentage of CD3 T cells at 1 and 2 months (1Mo and 2Mo, respectively) after adoptive transfer. ( D ) Percentage of CD4 and CD8 T cells present in circulation after adoptive transfer. ( E ) Representative flow cytometric analysis of blood CD3 T cells for the markers CD44 and CD127 at 2 months old after total T cell AT. ( F ) Representative MRI image of Nf1 f/f ; DhhCre neurofibroma bearing mice and Rag1 −/− ; Nf1 f/f ; DhhCre that were adoptively transferred with T cells or PBS as control. ( G ) Representative images of gross dissection of spinal cord with the associated neurofibromas of the dorsal root in 7-month-old Rag1 −/− ; Nf1 f/f ; DhhCre after adoptive transfer of pan-T cells. ( H ) Representative flow cytometric analysis for CD44 and CD127 of blood from Rag1 −/− ; Nf1 f/f ; DhhCre mice at 2 months old after adoptive transfer (AT) of CD8 or CD4 T cells. ( I ) Representative MRI image of Rag1 −/− ; Nf1 f/f ; DhhCre that were adoptively transferred with CD4 T cells or CD8 T cells alone. ( J ) Quantification of T cell recipient Rag1 −/− ; Nf1 f/f ; DhhCre mice that developed neurofibromas after adoptively transferred with or without total T cells or CD4 or CD8 T cells. ( K ) Predicted gene expression of CCL5 and its receptor CCR5 in immune cells of PNF tissue. m.o., months old. ( L ) CCL5 protein expression determined by flow cytometry of PNF tissue. Student’s t-test: *adj. * P < 0.05, *** P < 0.003, and **** P < 0.0001..

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Schematic of CD8 T cell depletion. ( B ) Flow cytometric quantification in the proportion of CD4 or CD8 of the total blood CD3 T cells in Nf1 f/f ; DhhCre compared to that in Rag1 −/− ; Nf1 f/f ; DhhCre. ( C ) Percentage of CD3 T cells at 1 and 2 months (1Mo and 2Mo, respectively) after adoptive transfer. ( D ) Percentage of CD4 and CD8 T cells present in circulation after adoptive transfer. ( E ) Representative flow cytometric analysis of blood CD3 T cells for the markers CD44 and CD127 at 2 months old after total T cell AT. ( F ) Representative MRI image of Nf1 f/f ; DhhCre neurofibroma bearing mice and Rag1 −/− ; Nf1 f/f ; DhhCre that were adoptively transferred with T cells or PBS as control. ( G ) Representative images of gross dissection of spinal cord with the associated neurofibromas of the dorsal root in 7-month-old Rag1 −/− ; Nf1 f/f ; DhhCre after adoptive transfer of pan-T cells. ( H ) Representative flow cytometric analysis for CD44 and CD127 of blood from Rag1 −/− ; Nf1 f/f ; DhhCre mice at 2 months old after adoptive transfer (AT) of CD8 or CD4 T cells. ( I ) Representative MRI image of Rag1 −/− ; Nf1 f/f ; DhhCre that were adoptively transferred with CD4 T cells or CD8 T cells alone. ( J ) Quantification of T cell recipient Rag1 −/− ; Nf1 f/f ; DhhCre mice that developed neurofibromas after adoptively transferred with or without total T cells or CD4 or CD8 T cells. ( K ) Predicted gene expression of CCL5 and its receptor CCR5 in immune cells of PNF tissue. m.o., months old. ( L ) CCL5 protein expression determined by flow cytometry of PNF tissue. Student’s t-test: *adj. * P < 0.05, *** P < 0.003, and **** P < 0.0001..

Techniques: Adoptive Transfer Assay, Control, Dissection, Expressing, Flow Cytometry

( A ) Experimental design of CD8 T cell depletion, in which, after adoptive transfer of CD8 T cells in Rag1 −/− ; Nf1 f/f DhhCre and confirming PNF development, CD8 antibody (Ab) or IgG control were administered once a week at 250 μg per mouse. ( B ) MRI images of Rag1 −/− ; Nf1 f/f ; DhhCre after CD8 T cell adoptive transfer confirming PNF development. ( C ) Flow cytometry of circulatory T cells after three treatment doses. ( D ) Gross dissection of mice after 2 months from treatment of CD8 antibody revealing reduced PNF formation. ( E ) Toluidine blue staining for mast cells of nerve or PNF sections. ( F ) Immunofluorescence of TCRβ for T cells and Iba-1 for macrophages in nerve or PNF. ( G ) Immunofluorescence of CCR5 (green) expressing F4/80 macrophages (red). ( H ) Flow cytometry of circulatory T cells after at the 6-month-old endpoint indicates reduced CD8 T cells mice treated with CD8 depletion antibody compared to that in IgG-treated control. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, and *** P < 0.003.

Journal: Science Advances

Article Title: Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

doi: 10.1126/sciadv.ado6342

Figure Lengend Snippet: ( A ) Experimental design of CD8 T cell depletion, in which, after adoptive transfer of CD8 T cells in Rag1 −/− ; Nf1 f/f DhhCre and confirming PNF development, CD8 antibody (Ab) or IgG control were administered once a week at 250 μg per mouse. ( B ) MRI images of Rag1 −/− ; Nf1 f/f ; DhhCre after CD8 T cell adoptive transfer confirming PNF development. ( C ) Flow cytometry of circulatory T cells after three treatment doses. ( D ) Gross dissection of mice after 2 months from treatment of CD8 antibody revealing reduced PNF formation. ( E ) Toluidine blue staining for mast cells of nerve or PNF sections. ( F ) Immunofluorescence of TCRβ for T cells and Iba-1 for macrophages in nerve or PNF. ( G ) Immunofluorescence of CCR5 (green) expressing F4/80 macrophages (red). ( H ) Flow cytometry of circulatory T cells after at the 6-month-old endpoint indicates reduced CD8 T cells mice treated with CD8 depletion antibody compared to that in IgG-treated control. Student’s t-test: *adj. * P < 0.05, ** P < 0.001, and *** P < 0.003.

Techniques: Adoptive Transfer Assay, Control, Flow Cytometry, Dissection, Staining, Immunofluorescence, Expressing

Immunohistochemistry slides of CD8+ TILs. ( A ) Baseline CD8+ TILs under ×200 magnification. Black arrows indicate iCD8+ TILs, and red arrows indicate sCD8+ TILs. Both intratumoral and stromal CD8+ TILs are diffusely distributed, with sCD8+ TILs being more abundant than iCD8+ TILs. ( B ) Baseline CD8+ TILs under ×400 magnification, showing positive staining of the cell membrane and cytoplasm (indicated by arrows).

Journal: Breast Cancer : Targets and Therapy

Article Title: The Correlation Between CD8+ Tumor-Infiltrating Lymphocytes and the Efficacy of Neoadjuvant Therapy in Breast Cancer

doi: 10.2147/BCTT.S533799

Figure Lengend Snippet: Immunohistochemistry slides of CD8+ TILs. ( A ) Baseline CD8+ TILs under ×200 magnification. Black arrows indicate iCD8+ TILs, and red arrows indicate sCD8+ TILs. Both intratumoral and stromal CD8+ TILs are diffusely distributed, with sCD8+ TILs being more abundant than iCD8+ TILs. ( B ) Baseline CD8+ TILs under ×400 magnification, showing positive staining of the cell membrane and cytoplasm (indicated by arrows).

Article Snippet: The CD8 rabbit anti-human polyclonal antibodies and secondary antibodies were sourced from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., and the immunohistochemistry staining kit was procured from Fuzhou Maixin Biotechnology Development Co., Ltd. Formalin-fixed, paraffin-embedded tissue sections were prepared according to standard procedures, including sectioning, deparaffinization, and rehydration.

Techniques: Immunohistochemistry, Staining, Membrane

Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

Journal: Experimental and Therapeutic Medicine

Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

doi: 10.3892/etm.2024.12730

Figure Lengend Snippet: Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

Techniques: Expressing, Microarray, Significance Assay

Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

Journal: Experimental and Therapeutic Medicine

Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

doi: 10.3892/etm.2024.12730

Figure Lengend Snippet: Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

Techniques: Immunohistochemical staining, Expressing

Journal: Theranostics

Article Title: Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis

doi: 10.7150/thno.53139

Figure Lengend Snippet: D-Nap-GFFY-T317 inhibits formation of urethane-induced lung tumors and atypical hyperplasia in WT but not IFNγ -/- mice. ( A ) WT or IFNγ -/- mice were randomly divided into 3 groups, and received following treatment: NC group, fed normal chow; TF group, fed normal chow containing T317 (5 mg/day/kg bodyweight); TH group, fed normal chow and s.c. injected D-Nap-GFFY once another day with dose of T317 at 10 mg/kg bodyweight or 5 mg/day/kg bodyweight. After one week of treatment, all the mice were i.p. injected urethane (1 g/kg bodyweight) once every 3 days for 8 times. After 126 days of the 1 st time urethane injection, all mice were sacrificed followed by collection of lung samples. ( B ) all lung samples were checked the tumor incidence on lung surface. ( C-D ) lung was photographed, the number of macroscopic external pulmonary nodules was counted. Arrows indicate the representative tumors. ( E-F ) after preparation, lung sections were conducted HE staining to determine tumor area with quantitative assay as % of whole section. ( G-L ) lung sections were conducted IHC staining to determine expression of Ki-67, TTF-1 and SPC with quantitative analysis of the average optical density (AOD) value (n ≥ 4). NEC: negative control, normal IgG was used to replace primary antibody. *P < 0.05, **P < 0.01, ***P < 0.001; NS: not significantly different. n = 14 for WT mice, n ≥ 8 for IFNγ -/- mice as indicated in Table .

Article Snippet: Rabbit anti-TTF-1, SPC, CD8a and VEGFR2 polyclonal antibodies were purchased from ABclonal Biotechnology Co., Ltd (Wuhan, Hubei, China).

Techniques: Injection, Staining, Immunohistochemistry, Expressing, Negative Control

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Concentrations of primary antibodies.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques: Concentration Assay

(A) HE(x200). (B) Immunohistochemical (IHC, x400) CD8+, CD4+, FOXP3+Tregs, and PD-L1 of Tonsil (positive tissue) and breast tumor. (C) Immunofluorescence (IF, x20) Blue: DAPI; Red: CD105; Green: NG2 (The short arrow shows microvessels not covered by pericyte cells, the long arrow shows microvessels covered by pericyte cells).

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: (A) HE(x200). (B) Immunohistochemical (IHC, x400) CD8+, CD4+, FOXP3+Tregs, and PD-L1 of Tonsil (positive tissue) and breast tumor. (C) Immunofluorescence (IF, x20) Blue: DAPI; Red: CD105; Green: NG2 (The short arrow shows microvessels not covered by pericyte cells, the long arrow shows microvessels covered by pericyte cells).

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques: Immunohistochemical staining, Immunofluorescence

Changes of sTILs, PD-L1, MVD, and MPI in non-pCR group and pCR group after NAC.

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Changes of sTILs, PD-L1, MVD, and MPI in non-pCR group and pCR group after NAC.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Univariate and multivariate analysis of pCR after NAC.

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Univariate and multivariate analysis of pCR after NAC.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Relationship between the baseline ratios of populations and pCR.

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: Relationship between the baseline ratios of populations and pCR.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

The relationship between the changes of sTILs, PD-L1, MVD, MPI, and DFS before and after NAC. (A) Survival analysis between pCR group and Non-pCR group. (B) Survival analysis of sTILs change. (C) Survival analysis of CD8+T change. (D) Survival analysis of CD4+T change. (E) Survival analysis of FOXP3+ Tregs change. (F) Survival analysis of PD-L1 change. (G) Survival analysis of MVD change. (H) Survival analysis of MPI change.

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: The relationship between the changes of sTILs, PD-L1, MVD, MPI, and DFS before and after NAC. (A) Survival analysis between pCR group and Non-pCR group. (B) Survival analysis of sTILs change. (C) Survival analysis of CD8+T change. (D) Survival analysis of CD4+T change. (E) Survival analysis of FOXP3+ Tregs change. (F) Survival analysis of PD-L1 change. (G) Survival analysis of MVD change. (H) Survival analysis of MPI change.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

The relationship between DFS and sTILs, PD-L1, MVD, and MPI in Metastatic lymph node (LN). (A) Survival analysis of LN sTILs. (B) Survival analysis of LN CD8+ T cells. (C) Survival analysis of LN CD4+ T cells. (D) Survival analysis of LN FOXP3+ Tregs. (E) Survival analysis of LN PD-L1. (F) Survival analysis of LN MVD. (G) Survival analysis of LN MPI.

Journal: Frontiers in Oncology

Article Title: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS

doi: 10.3389/fonc.2019.01545

Figure Lengend Snippet: The relationship between DFS and sTILs, PD-L1, MVD, and MPI in Metastatic lymph node (LN). (A) Survival analysis of LN sTILs. (B) Survival analysis of LN CD8+ T cells. (C) Survival analysis of LN CD4+ T cells. (D) Survival analysis of LN FOXP3+ Tregs. (E) Survival analysis of LN PD-L1. (F) Survival analysis of LN MVD. (G) Survival analysis of LN MPI.

Article Snippet: CD8 rabbit anti-human polyclonal antibody (17335-1-AP) , Proteintech, US , 1:1,000.

Techniques:

Review

Structured Review

Images

1) Product Images from "Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis"

Similar Products

Image Search Results